KRASG12C inhibition with sotorasib in advanced solid tumors
New England Journal of Medicine Sep 28, 2020
Hong DS, Fakih MG, Strickler JH, et al. - Researchers tested sotorasib as a therapeutic choice for patients with advanced solid tumors harboring the KRAS p.G12C mutation in this phase 1 trial. They treated patients with sotorasib given orally once daily. Safety was the primary endpoint. This study comprised dose escalation and expansion cohorts including 129 patients (59 with non–small-cell lung cancer, 42 with colorectal cancer, and 28 with other tumors). A median of 3 previous lines of anticancer therapies for metastatic disease were received by the patients. Findings demonstrated encouraging anticancer activity of sotorasib in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. In 11.6% of the patients, the occurrence of grade 3 or 4 treatment-related toxic impacts was reported.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries